Jan 30 |
CorMedix Inc. Announces Commercial and Reimbursement Updates
|
Dec 15 |
CorMedix Inc. Announces Appointment of Chief Legal Officer
|
Nov 15 |
CorMedix Inc. Announces FDA Approval of DefenCath® to Reduce the Incidence of Catheter-Related Bloodstream Infections in Adult Hemodialysis Patients
|
Nov 15 |
CorMedix rallies on FDA nod for anti-infective agent DefenCath
|
Nov 15 |
CorMedix Inc. (CRMD) Q3 2023 Earnings Call Transcript
|
Nov 14 |
Cormedix Inc (CRMD) Reports Increased Operating Expenses Amid Pre-Launch Activities in Q3 2023
|
Nov 14 |
CorMedix GAAP EPS of -$0.17 beats by $0.04
|
Nov 14 |
CorMedix Inc. Reports Third Quarter and Nine Month 2023 Financial Results and Provides Business Update
|
Nov 13 |
CorMedix Q3 2023 Earnings Preview
|